Food, Drugs, Healthcare, Life Sciences

On February 17, 2026, the U.S. Food and Drug Administration (FDA) approved FILKRI (filgrastim-laha)...

Today, the Supreme Court dealt a heavy blow to President Trump's trade agenda, concluding that the International Emergency Economic Powers Act...

On February 10, 2026, the World Health Organization ("WHO") prequalified a new novel oral polio vaccine type 2 ("nOPV2") product.

On February 11, 2026, Formycon AG and Lotus Pharmaceutical announced the execution of an exclusive license agreement directed to Formycon's pembrolizumab biosimilar candidate, FYB206.

Cowan, Liebowitz & Latman, P.C. celebrates Black History Month by celebrating the pioneering work of Dr. Charles Drew.

The Trump Administration continues to advocate for "Most Favored Nation" (MFN) pharmaceutical drug pricing through executive action and voluntary agreements, but the Administration's high-profile deals may have limited impact. To date, 16 manufacturers have signed voluntary agreements to adopt MFN prices. These deals will only apply to state Medicaid programs and cash-paying consumers, which limits their impact.

On February 17, 2026, the U.S. Food and Drug Administration (FDA) approved FILKRI (filgrastim-laha)...

Welcome to Health-e Law, Sheppard's podcast exploring the fascinating health tech topics and trends of the day. In this episode, partner and host Michael Orlando welcomes...

On February 3, 2026, the Department of Health and Human Services ("HHS") Office of Inspector General ("OIG")...